Geron Corporation (NASDAQ:GERN)
Industry: Healthcare

Geron Corporation operates as a biopharmaceutical company. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.

Current Quote*
Last: $3.480
Change: -0.110
Book: $6.147
Volume: 23,725

As Of: 07/19 16:00 ET
*Quotes delayed by 20min.

BuyIns.Net Alerts for Symbol GERN

Graphs for GERN

3 Month Graph

6 Month Graph

1 Year Graph